ABSTRACT
OBJECTIVE: A prospective cohort study in a teaching hospital to assess the efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced carcinoma cervix. METHOD: Neoadjuvant chemotherapy in the form of cisplatin 75 mg/m(2) and paclitaxel 135 mg/m(2) on day 1 and repeated at 14 days' interval for up to a maximum of three courses. RESULTS: Neoadjuvant chemotherapy in cervical cancer was effective in the downstaging of the disease. Downstaging was observed in 19.23 % of patients after two cycles and in 50 % of patients after three cycle of NACT. Operability increases to 33.3 and 38.4 % after two and three cycles of NACT, respectively. Complete pathological response was observed in 37.5 % of patients after NACT. No significant adverse effect in the feasibility of surgery was observed. CONCLUSION: The present study showed that neoadjuvant chemotherapy was an effective and well-tolerated mode of therapy with significantly less morbidity and mortality.
ABSTRACT
An intracardiac myxoma is the most common tumour of the heart with an estimated incidence of 0.5 per million population per year. Extensive calcification is rare in these tumours. We describe a rare case of a large left atrial myxoma, visible on the chest radiograph, with extensive calcification and osseous metaplasia.
Subject(s)
Calcinosis/pathology , Heart Neoplasms/pathology , Myxoma/pathology , Female , Heart Atria , Heart Neoplasms/surgery , Humans , Middle Aged , Myxoma/surgery , Ossification, Heterotopic/pathologyABSTRACT
⺠CA 125 is the most useful tumor marker for epithelial ovarian carcinoma. ⺠Very high serum CA 125 level does not necessarily indicate ovarian malignancy. ⺠Rapidly rising and persistent levels of CA 125 may be consistent with benign disease.
